Skip to main content

EU Kidney Consortium Proligen Awards Galapagos $665K Research Grant

NEW YORK (GenomeWeb News) - Galapagos has received a €500,000 ($665,000) grant from a European research consortium that aims to use genomics, proteomics, and functional genomics to help in the regeneration of injured kidneys, the company said today.
 
The grant was awarded by the Proligen consortium to Galapagos’ BioFocus DPI division, which identifies and validates drug targets and compound libraries using adenoviral agents.
 
The Proligen consortium is funded over three years with €2.5 million by the European Union’s Sixth Framework Program. Other Proligen members include universities and companies from Spain, Switzerland, the Netherlands, and Germany.
 
Under the terms of the deal, BioFocus will use its adenoviral libraries and cellular assay knowledge to target starting points for treatment of kidney injuries.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.